BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:225Ac-FPI-2068 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 225Ac-FPI-2068\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06147037-2306@assetmemo.bio
DTSTAMP:20261121T005947Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:225Ac-FPI-2068: Phase 1 readout est. (NCT06147037)
DESCRIPTION:225Ac-FPI-2068\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase 1\, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients Wi
 th Advanced Solid Tumours\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/225ac-fpi-2068#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06147037
URL:https://assetmemo.bio/drug/225ac-fpi-2068#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
